Roche agreed to acquire PathAI for up to $1.05 billion, aiming to accelerate use of AI in diagnostic workflows. Roche will pay $750 million upfront and up to $300 million in milestone-linked payments, with the deal expected to close in the second half of 2026 subject to approvals. The transaction builds on a partnership that began in 2021 and expanded in 2024, including AI-enabled companion diagnostic algorithm development. Roche said PathAI’s Image Management System (IMS) will be merged into its Diagnostics division to scale digital pathology globally. The move comes as biopharma increasingly integrates imaging and analytics into clinical decision-making. Roche framed the combined offering as a way to improve precision diagnosis and support biomarker discovery and clinical trial translational research. For competitors and partners in the digital pathology ecosystem, the deal raises the bar for platform integration and workflow deployment, not just algorithm performance.